Apixaban (2.5mg) & APIXAZEN 2.5 Mg : upto 30% discount by Sterispharma

Jun 17, 2024

Introduction

APIXAZEN 2.5 contains Apixaban 2.5 mg, a novel oral anticoagulant (NOAC) that selectively inhibits Factor Xa, reducing the risk of blood clot formation. It is used in patients at risk of thromboembolic events, including after major orthopedic surgery and in conditions like non-valvular atrial fibrillation.

Manufactured under WHO-GMP standards, APIXAZEN 2.5 offers:

Predictable anticoagulation
No need for INR monitoring
Minimal food and drug interactions

Composition

Active Ingredient: Apixaban 2.5 mg
Dosage Form: Film-coated oral tablet
Route of Administration: Oral

Indications & Uses

APIXAZEN 2.5 is indicated for:

VTE prevention after hip/knee replacement surgery
Extended DVT/PE prophylaxis after initial treatment
Stroke prevention in non-valvular atrial fibrillation (special populations)
Secondary prevention of thromboembolic events

Note: Often used in elderly patients, those with renal impairment, or low body weight.

Mechanism of Action

Apixaban selectively and reversibly inhibits Factor Xa, preventing the conversion of prothrombin to thrombin, and thus blocking clot formation.
It works independently of antithrombin III and provides a stable pharmacokinetic profile, enabling fixed-dose therapy without regular coagulation monitoring.

Dosage & Administration

Standard Dose: 2.5 mg twice daily

Surgical Prophylaxis:

Knee replacement: 10–14 days
Hip replacement: 28–35 days

Contraindications

Active bleeding
Severe hepatic impairment
Hypersensitivity to Apixaban
Concurrent use with strong CYP3A4 & P-gp inhibitors

Warnings & Precautions

Pre-surgical use: Discontinue temporarily
Renal impairment: Monitor function regularly
Bleeding risks: Caution in GI ulcers, recent surgery
Liver function: Not advised in severe hepatic disease

Possible Side Effects

Common:

Bruising, nosebleeds, bleeding gums
Nausea, anemia, indigestion

Serious (Rare):

Gastrointestinal or intracranial bleeding
Rash, hypersensitivity reactions
Elevated liver enzymes

Drug Interactions

Avoid with:

Strong CYP3A4 & P-gp inhibitors (e.g., ketoconazole, ritonavir)
Strong inducers (e.g., rifampicin, phenytoin)

Use cautiously with:

NSAIDs
Antiplatelet drugs (aspirin, clopidogrel)
SSRIs/SNRIs

Packaging

Strength: Apixaban 2.5 mg
Tablet: Round, biconvex, film-coated

Storage Instructions

Store below 25°C
Protect from moisture & sunlight
Keep out of reach of children

Frequently Asked Questions (FAQs)

Q. Can APIXAZEN 2.5 be taken with food?
Yes, it can be taken with or without food.

Q. Is blood monitoring required like with warfarin?
No. Apixaban does not require INR or routine coagulation monitoring.

Q. Can patients with kidney problems use APIXAZEN?
Yes, with caution. Dose adjustments may be required in moderate renal impairment.

Q. Can I stop taking it suddenly?
No. Sudden discontinuation may increase the risk of clot formation. Always consult your doctor.

Conclusion

APIXAZEN 2.5 (Apixaban 2.5 mg) offers an advanced, convenient, and clinically proven solution for thromboprophylaxis. Its predictable action, lower bleeding risk, and fixed-dose regimen make it a valuable choice in long-term anticoagulation therapy—especially for patients where safety and ease of use are paramount.

About The Author

STERIS HEALTHCARE PVT LTD

Steris Healthcare Pvt Ltd, known as Sterispharma, was founded in February 2018 by a team of experienced professionals in the pharmaceutical industry. Headquartered in Navi Mumbai, the company holds certifications from WHO, GMP, and ISO, reflecting its dedication to maintaining high standards of quality and safety. Sterispharma’s mission is to provide affordable, high-quality medications across India, strictly adhering to WHO guidelines. With the convenience of an online pharmacy, customers can easily order medicines with home delivery options.

For further information

Email: info@sterispharma.com / contact@sterispharma.com

Call/WhatsApp: 8209542042 , 8824175417

BUY NOW

SHARE WITH